Createrna Science and

Latest clinical program signals indexed for Createrna Science and.

1. TRIO041 — Phase 3

   Jun 8, 2026
   Clinical update →

2. AT148004 — Phase 2

   Jun 8, 2026
   Clinical update →

3. AT148003 — Phase 2

   Jun 8, 2026
   Clinical update →

4. LY06006/MRCT-301 — Phase 3

   Jun 8, 2026
   Clinical update →

5. BTIIMD-03-EC-23-DISC — Approved

   Jun 8, 2026
   Clinical update →

6. BSMO 1-2018 — Phase 2

   Jun 8, 2026
   Clinical update →

7. LOXO-BTK-20030 — Phase 3

   Jun 8, 2026
   Clinical update →

8. DF-006-1001 — Phase 1

   Jun 8, 2026
   Clinical update →

1. 2022-501969-42-00

   TRIO041

   Phase 3 · active · small_molecule

   Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria.

   CTIS ↗
2. 2022-502622-40-00

   A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors

   Phase 1 · active · other

   Advanced Solid Tumors

   CTIS ↗
3. 2023-503423-25-00

   HOVON 127 BL

   Phase 3 · active · small_molecule

   Burkitt lymphoma

   CTIS ↗
4. 2023-503829-18-00

   HO155

   Phase 2 · active · small_molecule

   Acute myeloid leukemia, Myelodysplastic syndrome

   CTIS ↗
5. 2023-504275-24-01

   Plasma rich in growth factors

   Approved · active · small_molecule

   Foot ulcers in diabetic patients with peripheral arterial disease

   CTIS ↗
6. 2023-504288-18-00

   DF-006-1001

   Phase 1 · active · other

   Chronic Hepatitis B

   CTIS ↗
7. 2023-505449-18-00

   HO159

   Phase 2 · active · small_molecule

   Patients with relapsed CLL, Chronic lymphocytic leukemia

   CTIS ↗
8. 2023-505514-15-00

   IMFINZI 50 mg/mL concentrate for solution for infusion.

   Phase 3 · active · small_molecule

   Small-cell lung cancer, extensive stage

   CTIS ↗
9. 2023-505746-25-00

   Zanubrutinib

   Phase 2 · active · small_molecule

   Cold agglutinin disease

   CTIS ↗
10. 2023-507357-15-00

    BTIIMD-02-EC-23-OJOS

    Approved · active · small_molecule

    Dry Eye Disease

    CTIS ↗
11. 2023-507357-15-01

    BTIIMD-02-EC-23-OJOS

    Approved · active · small_molecule

    Dry Eye Disease

    CTIS ↗
12. 2023-507429-41-00

    BTIIMD-03-EC-23-DISC

    Approved · active · small_molecule

    Low back pain

    CTIS ↗
13. 2023-507695-52-00

    LOXO-BTK-20019

    Phase 3 · active · small_molecule

    Mantle cell lymphoma

    CTIS ↗
14. 2023-507697-40-00

    LOXO-BTK-20020

    Phase 3 · active · small_molecule

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    CTIS ↗
15. 2023-507698-16-00

    LOXO-BTK-20022

    Phase 3 · active · small_molecule

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    CTIS ↗
16. 2023-507699-38-00

    LOXO-BTK-20030

    Phase 3 · active · small_molecule

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    CTIS ↗
17. 2023-507702-13-00

    SELPERCATINIB, SELPERCATINIB

    Phase 2 · active · small_molecule

    Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.

    CTIS ↗
18. 2023-507703-63-00

    LOXO-RET-18036

    Phase 2 · active · small_molecule

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    CTIS ↗
19. 2023-508340-22-00

    AT148003

    Phase 2 · active · small_molecule

    metastatic or unresectable, recurrent HNSCC

    CTIS ↗
20. 2023-508342-17-00

    AT148004

    Phase 2 · active · small_molecule

    metastatic or unresectable, recurrent HNSCC

    CTIS ↗
21. 2023-508818-42-00

    AC-203-EBS-007

    Phase 3 · active · small_molecule

    Generalized Epidermolysis Bullosa Simplex (EBS)

    CTIS ↗
22. 2023-509021-53-00

    Diamyd

    Phase 2 · active · small_molecule

    Latent Autoimmune Diabetes in Adults (LADA)

    CTIS ↗
23. 2023-509131-12-01

    EAE140

    Phase 2 · active · other

    Primary Immune Thrombocytopenia

    CTIS ↗
24. 2023-509270-37-00

    LOXO-BTK-18001 BRUIN

    Phase 2 · active · other

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    CTIS ↗
25. 2023-509406-30-00

    AT148006

    Phase 3 · active · small_molecule

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    CTIS ↗
26. 2023-509452-34-00

    Etrinabdione oral solution

    Phase 2 · active · small_molecule

    Peripheral Arterial Disease

    CTIS ↗
27. 2024-511599-33-00

    LOXO-BTK-20023

    Phase 3 · active · small_molecule

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    CTIS ↗
28. 2024-513229-22-00

    ALKS4230-006

    Phase 2 · active · small_molecule

    Advanced cutaneous melanoma and Advanced mucosal melanoma

    CTIS ↗
29. 2024-513230-38-00

    ALKS 4230-007

    Phase 3 · active · small_molecule

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    CTIS ↗
30. 2024-513591-18-00

    LY06006/MRCT-301

    Phase 3 · active · small_molecule

    Postmenopausal osteoporosis

    CTIS ↗
31. 2024-514991-41-01

    GEMCITABINE

    Phase 2 · active · small_molecule

    Upper Tract Urothelial Carcinoma. Upper urinary tract transitional cell carcinoma

    CTIS ↗
32. 2024-515166-14-00

    BASICstudy

    Phase 3 · active · small_molecule

    Chronic cluster headache

    CTIS ↗
33. 2024-515634-32-00

    EAE120

    Phase 2 · active · small_molecule

    newly diagnosed multiple myeloma

    CTIS ↗
34. 2024-515755-37-00

    Tecentriq 1 200 mg concentrate for solution for infusion

    Phase 2 · active · small_molecule

    Limited disease small-cell lung cancer

    CTIS ↗
35. 2024-515914-41-00

    Mecasermin rinfabate

    Phase 2 · active · small_molecule

    Chronic Lung Disease

    CTIS ↗
36. 2024-515988-55-00

    EAE-2020/MM0107

    Phase 2 · active · small_molecule

    Newly diagnosed multiple myeloma

    CTIS ↗
37. 2024-516060-28-00

    EAE 115

    Phase 2 · active · small_molecule

    Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor"

    CTIS ↗
38. 2024-516061-36-00

    EAE116

    Phase 2 · active · small_molecule

    Newly diagnosed patients with multiple myeloma and severe renal impairment

    CTIS ↗
39. 2024-516147-32-00

    EAE127

    Phase 2 · active · small_molecule

    Relapsed/refractory multiple myeloma

    CTIS ↗
40. 2024-517723-39-00

    EAE128

    Phase 2 · active · small_molecule

    Newly diagnosed patients with multiple myeloma

    CTIS ↗
41. 2024-518263-35-00

    54767414LEU2002

    Phase 2 · active · small_molecule

    Primary plasma cell leukemia

    CTIS ↗
42. 2024-518495-31-00

    177Lu PSMA I&T solution for injection

    Phase 2 · active · small_molecule

    Recurrent grade 3 and grade 4 glioma

    CTIS ↗
43. 2024-518522-32-00

    BSMO 1-2018

    Phase 2 · active · small_molecule

    Basket tumors

    CTIS ↗
44. 2024-518581-27-00

    A Study to evaluate the effect of a high-fat... for Healthy volunteer

    Phase 1 · active · other

    Healthy volunteer

    CTIS ↗
45. 2024-518668-11-01

    ExPlas

    Phase 2 · active · small_molecule

    Early symptomatic phase Alzheimer's disease

    CTIS ↗
46. 2024-518877-33-00

    SCO101-001

    Phase 2 · active · small_molecule

    Metastatic Colorectal Cancer

    CTIS ↗
47. 2024-518915-20-00

    TRS-2019-00002051

    Approved · active · small_molecule

    Type 2 diabetes mellitus

    CTIS ↗
48. 2024-519004-27-00

    DT-DEC01

    Phase 2 · active · small_molecule

    Duchenne Muscular Dystrophy

    CTIS ↗
49. 2025-521008-22-00

    Piqray 50 mg and 200 mg film-coated tablets

    Phase 2 · active · small_molecule

    metasatic breast cancer, hormon positive, her 2 negative

    CTIS ↗
50. 2025-521875-30-00

    Xospata 40 mg film-coated tablets

    Phase 2 · active · small_molecule

    Acute myeloid leukaemia, Acute myeloid leukaemia

    CTIS ↗
51. 2025-523273-41-00

    TD001

    Phase 2 · active · small_molecule

    Metastatic castration-resistant prostate cancer

    CTIS ↗